iZafe Group AB brings forward publication of interim report for the second quarter of 2026

IZAFE BSelskabsmeddelelse25.08.2026, 07.30

iZafe Group AB, reg. no. 556762-3391 (“iZafe” or the “Company”), has resolved to bring forward the publication of its interim report for the second quarter of 2026 to Monday, August 31, 2026, from the previously communicated date.

The change of publication date is due to the work on the interim report having been completed earlier than planned.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com